Determine the necessary mass, volume, or concentration for preparing a solution.
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
SKU | Size | Availability | Price | Qty |
---|---|---|---|---|
M413601-1mg | 1mg | In stock | $78.90 | |
M413601-5mg | 5mg | In stock | $187.90 | |
M413601-10mg | 10mg | In stock | $305.90 | |
M413601-25mg | 25mg | In stock | $612.90 | |
M413601-50mg | 50mg | In stock | $899.90 |
OX Receptor Antagonists
Synonyms | AC-36061 | BCP19608 | SB16800 | Urokinase inhibitor 1 | A16360 | AS-74199 | D84025 | GTPL9306 | 1207253-08-4 | CS-5968 | MK1064 | mk-1064 | UNII-O812716S9E | PENTAMIDINE ISETHIONATE [USP-RS] | BDBM50028059 | (2,2':5',3''-Terpyridine)-3'-carboxamide, 5''-c |
---|---|
Specifications & Purity | Moligand™, ≥98% |
Biochemical and Physiological Mechanisms | MK1064 is a selective orexin\u20052 receptor antagonist (2-SORA) with an IC50 of 18 nM. |
Storage Temp | Store at -20°C |
Shipped In | Ice chest + Ice pads |
Grade | Moligand™ |
Action Type | ANTAGONIST |
Mechanism of action | Antagonist of OX 1 receptor;Antagonist of OX 2 receptor |
Product Description | Information MK1064 MK1064 is a selective orexin 2 receptor antagonist (2-SORA) with an IC50 of 18 nM. Targets orexin\u20052 receptor 18 nM |
ALogP | 3.298 |
---|---|
HBD Count | 1 |
Rotatable Bond | 7 |
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|---|---|---|---|---|---|---|
Tyrosine-protein kinase ABL inhibitor | INHIBITOR | ALA1862 | Tyrosine-protein kinase ABL | SINGLE PROTEIN | Homo sapiens | DailyMed: [1] | |
Tyrosine-protein kinase ABL inhibitor | INHIBITOR | ALA1862 | Tyrosine-protein kinase ABL | SINGLE PROTEIN | Homo sapiens | DailyMed: [1] | |
Tyrosine-protein kinase ABL inhibitor | INHIBITOR | ALA1862 | Tyrosine-protein kinase ABL | SINGLE PROTEIN | Homo sapiens | Expert: [1] | |
Tyrosine-protein kinase ABL inhibitor | INHIBITOR | ALA1862 | Tyrosine-protein kinase ABL | SINGLE PROTEIN | Homo sapiens | ||
Tyrosine-protein kinase ABL inhibitor | INHIBITOR | ALA1862 | Tyrosine-protein kinase ABL | SINGLE PROTEIN | Homo sapiens | ||
Tyrosine-protein kinase ABL inhibitor | INHIBITOR | ALA1862 | Tyrosine-protein kinase ABL | SINGLE PROTEIN | Homo sapiens | ||
Tyrosine-protein kinase ABL inhibitor | INHIBITOR | ALA1862 | Tyrosine-protein kinase ABL | SINGLE PROTEIN | Homo sapiens | ||
Tyrosine-protein kinase ABL inhibitor | INHIBITOR | ALA1862 | Tyrosine-protein kinase ABL | SINGLE PROTEIN | Homo sapiens | ||
Tyrosine-protein kinase ABL inhibitor | INHIBITOR | ALA1862 | Tyrosine-protein kinase ABL | SINGLE PROTEIN | Homo sapiens | ||
Tyrosine-protein kinase ABL inhibitor | INHIBITOR | ALA1862 | Tyrosine-protein kinase ABL | SINGLE PROTEIN | Homo sapiens | PubMed: [1] |
IUPAC Name | 5-(5-chloropyridin-3-yl)-N-[(5,6-dimethoxypyridin-2-yl)methyl]-2-pyridin-2-ylpyridine-3-carboxamide |
---|---|
INCHI | InChI=1S/C24H20ClN5O3/c1-32-21-7-6-18(30-24(21)33-2)14-29-23(31)19-10-16(15-9-17(25)13-26-11-15)12-28-22(19)20-5-3-4-8-27-20/h3-13H,14H2,1-2H3,(H,29,31) |
InChi Key | CKTWQGHVNRYNCM-UHFFFAOYSA-N |
Canonical SMILES | COC1=C(N=C(C=C1)CNC(=O)C2=C(N=CC(=C2)C3=CC(=CN=C3)Cl)C4=CC=CC=N4)OC |
Isomeric SMILES | COC1=C(N=C(C=C1)CNC(=O)C2=C(N=CC(=C2)C3=CC(=CN=C3)Cl)C4=CC=CC=N4)OC |
PubChem CID | 44633765 |
Molecular Weight | 461.9 |
PubChem CID | 44633765 |
---|---|
ChEMBL Ligand | CHEMBL3338866 |
CAS Registry No. | 1207253-08-4 |
BindingDB Ligand | 50028059 |
GPCRdb Ligand | MK-1064 |
Enter Lot Number to search for COA:
Find and download the COA for your product by matching the lot number on the packaging.
5 results found
Lot Number | Certificate Type | Date | Item |
---|---|---|---|
H2213273 | Certificate of Analysis | Jun 04, 2022 | M413601 |
H2213283 | Certificate of Analysis | Jun 04, 2022 | M413601 |
H2213284 | Certificate of Analysis | Jun 04, 2022 | M413601 |
H2213285 | Certificate of Analysis | Jun 04, 2022 | M413601 |
H2213286 | Certificate of Analysis | Jun 04, 2022 | M413601 |
Solubility | Solubility (25°C) In vitro DMSO: 92 mg/mL (199.17 mM); Water: Insoluble; Ethanol: Insoluble; |
---|---|
DMSO(mg / mL) Max Solubility | 92 |
DMSO(mM) Max Solubility | 199.1773111063 |
Water(mg / mL) Max Solubility | <1 |
Pictogram(s) | GHS08 |
---|---|
Signal | Warning |
Hazard Statements | H373:Causes damage to organs through prolonged or repeated exposure H371:May cause damage to organs |
Precautionary Statements | P405:Store locked up. P501:Dispose of contents/container to ... P264:Wash hands [and …] thoroughly after handling. P260:Do not breathe dust/fume/gas/mist/vapors/spray. P270:Do not eat, drink or smoke when using this product. P308+P316:IF exposed or concerned: Get emergency medical help immediately. P319:Get medical help if you feel unwell. |
1. Roecker AJ, Mercer SP, Schreier JD, Cox CD, Fraley ME, Steen JT, Lemaire W, Bruno JG, Harrell CM, Garson SL et al.. (2014) Discovery of 5''-chloro-N-[(5,6-dimethoxypyridin-2-yl)methyl]-2,2':5',3''-terpyridine-3'-carboxamide (MK-1064): a selective orexin 2 receptor antagonist (2-SORA) for the treatment of insomnia.. ChemMedChem, 9 (2): (311-22). [PMID:24376006] [10.1021/op500134e] |
2. Gotter AL, Forman MS, Harrell CM, Stevens J, Svetnik V, Yee KL, Li X, Roecker AJ, Fox SV, Tannenbaum PL et al.. (2016) Orexin 2 Receptor Antagonism is Sufficient to Promote NREM and REM Sleep from Mouse to Man.. Sci Rep, 6 (13): (27147). [PMID:27256922] [10.1021/op500134e] |